<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558960</url>
  </required_header>
  <id_info>
    <org_study_id>RB-001-HMO-CTIL</org_study_id>
    <nct_id>NCT01558960</nct_id>
  </id_info>
  <brief_title>Intravitreal Injections of Melphalan for Retinoblastoma</brief_title>
  <official_title>Intravitreal Injections of Melphalan for Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinoblastoma treatment has become more and more focused in the last years. New treatments
      developed by Dr. Kaneko from Japan in 1995 are now being tested in clinical trials.

      Intra-arterial chemotherapy with Melphalan has shown success in some patients but with
      limited response when there is marked vitreal seeding. For these cases Intravitreal
      injections of Melphalan have been successful in Japan.

      In this study the same chemotherapy (melphalan) will be administered intravitreally (directly
      through the eye wall) and the response (short and long term) will be monitored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal injections of Melphalan will be given to cases unresponsive to chemotherapy or
      with vitreal seeding of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sufficient findings to draw conclusions
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment response</measure>
    <time_frame>1 year</time_frame>
    <description>short term response to treatment and long term complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>1 year</time_frame>
    <description>short and long term complications</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>IVit Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injections of Melphalan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVit Melphalan</intervention_name>
    <description>IVit injections of Melphalan</description>
    <arm_group_label>IVit Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Retinoblastoma that has not responded to chemotherapy

          -  Retinoblastoma that has vitreal seeding

        Exclusion Criteria:

          -  previous failure of IVit Melphalan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahar Frenkel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah-Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinoblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

